INGREZZA® (valbenazine) capsules is the only once-daily treatment for adults with tardive dyskinesia
Help your adult patients with Tardive Dyskinesia (TD)


Not actual size

INGREZZA is the simple, once-daily choice to reduce TD severity1
Actor portrayal
THE SIMPLE CHOICE
Once-daily INGREZZA is the simple choice to support patient adherence1,2,*
EXPLORE DOSINGSYMPTOM REDUCTION
INGREZZA 80 mg reduced uncontrolled movements in 7 of 10 patients at 6 weeks (post hoc analysis)1,3,†
REVIEW EFFICACYSAVINGS & SUPPORT
$10 or less out-of-pocket is what most patients pay for INGREZZA4
SEE SUPPORT OPTIONS* | Based on a meta-analysis of 51 studies comparing timing adherence of once-daily vs twice-daily regimens for chronic conditions. |
† | Post hoc analysis included patients who had a baseline and a Week 6 AIMS total score. Reduction in uncontrolled movements as assessed by ≥1-point decrease in AIMS total score. |

TREAT FIRST LINE WITH VMAT2 INHIBITORS
VMAT2 inhibitors, like INGREZZA, are recommended as first-line treatment for TD6-8
SEE GUIDELINESACCESS EXCLUSIVE TARDIVE DYSKINESIA (TD) RESOURCES
Register for access to TD resources, including real-world patient videos and clinical trial videos showing INGREZZA treatment results
SIGN UPREFERENCES:
- INGREZZA [package insert]. San Diego, CA: Neurocrine Biosciences, Inc
- Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527-539
- Data on file. Neurocrine Biosciences, Inc
- Data on file as of Q1 2021. Neurocrine Biosciences, Inc
- Data on file as of Q3 2021. Neurocrine Biosciences, Inc
- Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. 3rd ed. American Psychiatric Association Publishing, 2020
- Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S. Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389:67-75
- Caroff SN, Citrome L, Meyer J, et al. A modified Delphi consensus study of the screening, diagnosis, and treatment of tardive dyskinesia. J Clin Psychiatry. 2020;81(2):19cs12983